clicode Index
Menus du Forum :

Sujet précédent :: Sujet suivant
Auteur Message

Hors ligne
Inscrit le: 17 Juil 2014
Messages: 293
Parrain: Aucun
Point: 0
Moyenne de points: 0,00

MessagePosté le: Lun 25 Aoû - 09:49 (2014) Sujet du message: A nonlinear stochastic model can depict protein protein int Répondre en citant

 twenty and energy of 0. 80. This assumed a 50% improvement in median PFS from five. 0 months in arm III to 7. 5 months in arm I or II, and twelve month accrual time and 6 month comply with up. The hazard ratio and its 95% CI had been estimated. A stratified log rank check was utilised to evaluate PFS in between the therapy arms, having said INNO-406 ic50 that, the P values had been for reference only. Secondary endpoints included OS, ORR, duration of tumor response, PROs, and security. ORR in between remedy arms was in contrast utilizing Cochran Mantel Haenszel test stratified by baseline ECOG PS and gender. Descriptive summary statistics on the MDASI items have been reported. Safety was analyzed in sufferers who received at least 1 dose of research drug, along with the outcomes from only the randomized phase II portion have been presented right here.

The LBH589 efficacy and security analyses were initially con ducted primarily based on the information obtained as of March one, 2011, when the examine was even now ongoing. PFS and general safety were later on up to date utilizing a information cutoff date of December axitinib servicing therapy. From the completion from the study, all patients discontinued the research, mainly as a result of death. Efficacy The investigator assessed median PFS was months in arms I, II, and III, respectively. The hazard ratio was 0. 89 for arm I 21, 2011, which are presented here. It ought to be noted that median PFS in every single arm were quite comparable amongst the two analyses.

The final examination for OS, duration of tumor response amid responders, amount of deaths, and significant AEs was carried out following オーダー LY2109761 the database lock on Might 18, 2012. For each endpoint, by far the most updated benefits are presented within this manuscript. Outcomes Patient traits Concerning January 19, 2009 and April 21, 2010, a complete of 170 individuals had been randomly assigned amid 3 treat ment arms, arm I, arm II, and arm III. All patients have been handled with assigned medication, except two individuals in arm III who did not receive pemetrexed cisplatin. Amongst sufferers throughout the three therapy arms, the median age was similar. The majority of patients had been white and male, and diagnosed with stage IV NSCLC. Smokers comprised 73%, 84%, and 79% of sufferers in arms I, II, and III, respectively.

Therapy The median quantity of cycles for pemetrexed and cis platin was very similar across all treatment method arms, five cycles each and every in arm I, 6 and 5 cycles, respectively, in arm II, and 6 cycles every single in arm III. The median of axitinib treatment method cycles was 8 in arm I and 6. five in arm II. Sufferers in arm I received axitinib treatment method longer than these in arm II. One particular or far more axitinib dose interruptions were reported in 87% of pa tients in arm I and 97% in arm II, of which 76% and 69%, respectively, were on account of AEs. Median relative axitinib dose intensity was 92% in arm I and 104% in arm II. Median relative dose intensity was similar between the three arms for pemetrexed and for cisplatin. Following blend therapy, 58% of pa tients in arm I and 50% in arm II received single agent versus arm III, and 1. 02 for arm II versus arm III. Median OS was 17. 0, 14. 7, and 15. 9 months in arms I, II, and III, respectively. Total confirmed ORRs was 45. 5% and 39.

Revenir en haut


MessagePosté le: Lun 25 Aoû - 09:49 (2014) Sujet du message: Publicité

PublicitéSupprimer les publicités ?
Revenir en haut
Montrer les messages depuis:
Toutes les heures sont au format GMT + 2 Heures
Poster un nouveau sujet Répondre au sujet
Page 1 sur 1
Navigation :

Sauter vers:  
Moderation du Forum :
Supprimer - Déplacer - Verrouiller - Diviser
Que pouvez vous faire dans ce Forum ? :

Index | Panneau d’administration | Creer un forum | Forum gratuit d’entraide | Annuaire des forums gratuits | Signaler une violation | Conditions générales d'utilisation
Template Easy blue by Fly Center
Powered by phpBB © 2001,2002 phpBB Group - Traduction par